SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: MEDIAN Technologies (Paris:ALMDT), a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, announced today it has been selected as the imaging solutions provider in a new phase II clinical trial for a global biopharmaceutical company. As part of the project, imaging data will be acquired in more than 100 clinical sites located in 14 countries worldwide. Anticipated total enrollment is 300 patients with a forecasted project start by year end.
